Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of British Columbia

$27,000.00

Cost-Effectiveness Analysis of Immunotherapy as a First-Line Treatment vs Standard Therapy in Cancer Based on a Canadian Healthcare Setting ( The exact topic will be finalized with the supervisor)

EF 2025-26

Résumé
The rising cost of oncology drugs has intensified pressure on the Canadian public health system. The most newly approved therapies, specifically for cancer, come with very high treatment costs (over CAD 10,000). This complexity is exacerbated by the growing economic burden of cancer in Canada, which reached CAD 26 billion in 2021. Economic evaluations are essential for resource allocation; however, Canada-specific economic evaluations remain limited, particularly those integrating real-world cost data, utility values, and survival outcomes relevant to Canadian public payers. My research motivation builds directly on this gap. Through my previous research at Tehran University of Medical Sciences, using TreeAge Pro and R, I conducted two long-term model-based evaluations of novel cancer therapies, commissioned by the Iranian Food and Drug Administration (IFDA). The primary objective is to conduct a cost-effectiveness analysis (CEA) of immunotherapy vs. standard treatment in Canada. First, a systematic literature review will be performed, following the PRISMA flow diagram, and the specific RCT will be selected. Cost data will then be gathered from Canadian sources. Then, a 3-state Markov model in R will be developed with a lifetime horizon, applying a 1.5% discount rate and according to CHEERS standards. Also, uncertainty will be assessed through Monte Carlo and one-way sensitivity analysis to assess the uncertainty of the data. Ultimately, this study highlights the urgent need for localized pharmacoeconomic evaluations. Results will bridge clinical innovation with economic evaluation by generating Canadian-specific ICERs, which will effectively benefit policymakers with insights for pricing, budget planning, and insurance decisions.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
582776
Name
Mashreghi Mohammadi neshat
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Cost-Effectiveness Analysis of Immunotherapy as a First-Line Treatment vs Standard Therapy in Cancer Based on a Canadian Healthcare Setting ( The exact topic will be finalized with the supervisor)
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cost-Effectiveness Analysis; Cost-Utility Analysis; Drug Policy And Access; Economic Evaluation Of Pharmaceuticals; Health Economics; Health Outcomes Research; Health Technology Assessment (Hta); Healthcare Resource Allocation; Pharmacoeconomics; Real-World Evidence
Abstract
The rising cost of oncology drugs has intensified pressure on the Canadian public health system. The most newly approved therapies, specifically for cancer, come with very high treatment costs (over CAD 10,000). This complexity is exacerbated by the growing economic burden of cancer in Canada, which reached CAD 26 billion in 2021. Economic evaluations are essential for resource allocation; however, Canada-specific economic evaluations remain limited, particularly those integrating real-world cost data, utility values, and survival outcomes relevant to Canadian public payers. My research motivation builds directly on this gap. Through my previous research at Tehran University of Medical Sciences, using TreeAge Pro and R, I conducted two long-term model-based evaluations of novel cancer therapies, commissioned by the Iranian Food and Drug Administration (IFDA). The primary objective is to conduct a cost-effectiveness analysis (CEA) of immunotherapy vs. standard treatment in Canada. First, a systematic literature review will be performed, following the PRISMA flow diagram, and the specific RCT will be selected. Cost data will then be gathered from Canadian sources. Then, a 3-state Markov model in R will be developed with a lifetime horizon, applying a 1.5% discount rate and according to CHEERS standards. Also, uncertainty will be assessed through Monte Carlo and one-way sensitivity analysis to assess the uncertainty of the data. Ultimately, this study highlights the urgent need for localized pharmacoeconomic evaluations. Results will bridge clinical innovation with economic evaluation by generating Canadian-specific ICERs, which will effectively benefit policymakers with insights for pricing, budget planning, and insurance decisions.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mashreghi Mohammadi, neshat
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~